We use necessary cookies to make our website work. We also use optional statistical, functional and marketing cookies that you can choose to decline in your preference setting. For more information about the use of cookies or our use of data, see our Cookies notice or Privacy notice

Cookies settings I agree I disagree

Cookies information

Our site uses tools, such as cookies, to analyze and improve your experience. You can unsubscribe below:

Statistic

We use tools such as Google Analytics to track web traffic and check the effectiveness of our site.

Necessary

Cookies required for essential services and features such as login forms, shopping cart integration and access control. Without them, our website cannot function properly and we cannot provide any services. Deactivation is not available.

These settings will be kept for 24h

Publications

Evaluation of the effects of a novel contact pathway inhibitor, Ir-CPI, on in vitro platelet function and coagulation

Evaluation of the effects of a novel contact pathway inhibitor, Ir-CPI, on in vitro platelet function and coagulation
Publications
Evaluation of the effects of a novel contact pathway inhibitor, Ir-CPI, on in vitro platelet function and coagulation

Abstract ISTH 2015

Jayaprakash KothaA, Juan Manuel CardenasA, Michael HerrA, Vinay BhalA, Mason DixonA, Melanie WhiteA, Sophie CombeB, Edmond GodfroidB, Lisa JenningsC

  • A
    CirQuest Labs, Memphis, TN, USA
  • B
    Bioxodes, Marche-en-Famenne, Belgium
  • C
    The University of Tennessee Health Science Center, Memphis, TN, USA

Documents

Poster

Background

Ir-CPI, the tick Ixodes ricinus salivary protein, is a serine protease inhibitor under development as a novel anticoagulant. Ir-CPI inhibits Factors (F) XIIa, XIa, and kallikrein generation, prolongs the activated partial thromboplastin time, and confers antithrombotic activity in preclinical models.

Aim

The study aim was to test Ir-CPI effects on platelet function using light transmission aggregometry (LTA), clot retraction, and Pselectin expression and to characterize Ir-CPI inhibition of the contact activated coagulation pathway by assessing FXa and FIXa activation time and activity.

Methods

Ir-CPI effects on LTA in response to 20 µM ADP and 1.6 mM arachidonic acid (AA) were studied using consented blood donors (n = 5). Platelet P-selectin expression was evaluated using flow cytometry (n = 4) following activation by contact pathway initiation. Ir-CPI effects on PRP clot retraction was measured (n = 5), and FXa and FIXa generation were determined by quantitative chromogenic assays (n = 3).

Results

LTA response as well as clot retraction were unaffected by Ir-CPI pretreatment. However, the percent of P-selectin positive platelets was decreased following Ir-CPI treatment (0.5, 1, and 2 µM) by 5%, 9%, and 18%, respectively, vs. control. FXa activation lag times were prolonged to 704, 752, 826, 1013 s with increasing concentrations of Ir-CPI (1, 2, 4, 8 µM, respectively) vs. control (611 s). Similarly, FIXa activation lag times were 790, 834, 876, and 902 s, respectively, vs. 581 s (control). Also, the mean reaction rates (OD min -1) of FXa and FIXa with added Ir-CPI were decreased ~2.3-fold.

Conclusion

We demonstrated that Ir-CPI does not affect in vitro platelet aggregation response or clot retraction. However, Ir-CPI dose dependently blocked contact pathway mediated platelet P-selectin expression and the rate of FXa and FIXa activation and activity. This study confirms specific effects of Ir-CPI on the contact pathway of coagulation and provides a basis for monitoring Ir-CPI.